Ipsen Biopharmaceuticals, Inc.
650 E Kendall Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
464 articles with Ipsen Biopharmaceuticals, Inc.
Ipsen Announces Eight Oral Presentations from Its Neurosciences Portfolio at the 10th World Congress for Neurorehabilitation (WCNR)
The meeting takes place in Mumbai, India, February 7-10, 2018.
Ipsen to Present Data at ASCO GI 2018, Including New Post-Hoc Analyses from ONIVYDE (irinotecan liposome injection) Phase III NAPOLI-1 Trial
Ipsen announced that five new sub-analyses of the pivotal Phase 3 NAPOLI-1 trial will be presented at this year’s American Society of Clinical Oncology’s Gastrointestinal Cancer Symposium (ASCO GI) taking place in San Francisco, California, from January 18-20.
The data will be presented during an oral session on Friday, January 19 at the 2018 ASCO-GI.
Ipsen announced that irinotecan liposome injection (Onivyde), cabozantinib (Cabometyx), lanreotide (Somatuline Autogel / Depot), and telotristat ethyl (Xermelo) are the subject of 11 posters, along with 2 others focusing on patients living with neuroendocrine tumors, at the 2018 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO-GI), January 18-20, 2018 in San Francisco (CA, USA).
Mr Paulson will assume oversight of all areas supporting the North American business effective from February 5th.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care.
Ipsen Announces Publication in Neurology of Results of Two Studies Demonstrating the Efficacy and Safety Of Dysport (Abobotulinumtoxina) in Adult Patients With Lower Limb Spasticity
Results led to regulatory approval of Dysport for the treatment of lower limb spasticity in adults in the U.S. in 2017 and in some European countries in 2016.
Ipsen Delivers Strong Sales Growth of 22.6% for the Third Quarter of 2017 and Confirms Full Year Guidance
Ipsen, a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2017.
Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma
Ipsen and its partner Exelixis today announced that its global phase 3 CELESTIAL trial met its primary endpoint of overall survival (OS)
Ipsen Announces Five Poster Presentations Of Dysport (Abobotulinumtoxina) Data At The 2017 American Academy Of Physical Medicine And Rehabilitation (AAPM&R) Annual Assembly
Ipsen Announces Four Poster Presentations Of Dysport (Abobotulinumtoxina) Data At The 2017 Child Neurology Society Annual Meeting
Ipsen Receives Approval From European Commission (EC) For Xermelo (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Patients Inadequately Controlled By Somatostatin Analogue Therapy
U.S. FDA Approves New Indication For Ipsen's Somatuline Depot (Lanreotide) Injection For The Treatment Of Carcinoid Syndrome
Ipsen Announces Analysis Of Managed Medicaid Data Of Children With Cerebral Palsy At Annual Meeting Of The American Academy Of Cerebral Palsy And Developmental Medicine
Ipsen Announces Oral And Poster Presentations Of Abobotulinumtoxina Data At The 2017 Annual Meeting Of The American Academy Of Cerebral Palsy And Developmental Medicine
Ipsen And Exelixis Announce Results From Phase II Cabosun Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma At ESMO 2017
Ipsen Announces 16 Abstract Presentations Of Oncology Portfolio At European Society Of Medical Oncology Congress